The Clinical Obeservation Of Treating Refractory Anemia Of Myelodysplastic Syndrome Mainly With Marrow-Supplementing And Blood-Engendering Granule

This thesis paper summarizes the treatment and study on Myelodysplastic Syndrome (abbreviated as MDS) in recent years, then makes a clinical observation and study on 40 Refractory Anemia (abbreviated as RA) patients, using marrow- supplementing and blood-engendering granule plus all-trans retinoic acid as therapeutic medicine, and summarizes therapeutic principle of marrow- supplementing and blood-engendering granule to MDS-RA.After study we find that total MDS-RA therapeutic effect rate in treatment group is 76.19 %, which is superior to that of the controlled group (42.11%), there is significant differences between two groups (P<0.05).After treatment, there is significant improvement of anemia and hemorrhage symptom in treatment group, and compared with that before treatment, the differences is significant (P<0.05), and the improvement degree is superior to that in the controlled group (P<0.05).After treatment, there is significant improvement of peripheral blood in treatment group, and compared with that before treatment, the differences is significant (P<0.01), and the improvement degree is superior to that in the controlled group.After treatment, there is significant discrease of immature cells in peripheral blood and bone marrow in treatment grpup, and compared with that before treatment, the differences is significant (P<0.01), and the improvement degree is superior to tha.t in the controlled group.After treatment, there is significant improvement of morbidgenerating blood phenomenon in both peripheral blood and bone marrow in treatment group, and compared with that before treatment, the differences is significant (P<0.01), and the improvement degree is superior to that in the controlled group (P<0.05).The result above shows marrow-supplementing and blood-engendering granule can effectively improve anemia and hemorrhage symptom and peripheral blood, decrease immature cells in peripheral blood and bone marrow, the degree of which is superior to that in controlled group, and shows marrow-supplementing and blood-engendering granule is an effective prescription for treating MDS-RA.